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 Abstract  Adrenomedullin (AM) was originally isolated from human pheochromo-
cytoma as a biologically active peptide with potent vasodilating action, but it also 
has a wide range of physiological properties including cardiovascular protection, 
neovascularization, and the ability to suppress apoptosis. It is constitutively 
produced by various tissues including the gastrointestinal tract. AM production and 
secretion can be induced by pro-inﬂ ammatory cytokines such as tumor necrosis 
factor-α and interleukin-1, as well as by lipopolysaccharide. Conversely, AM causes 
the downregulation of inﬂ ammatory cytokines in cultured cells and downregulates 
inflammatory processes in various models of colitis, including those induced 
by acetic acid and by dextran sulfate sodium. AM works by exerting anti-inﬂ ammatory 
and antibacterial effects and by stimulating mucosal regeneration and supporting 
maintenance of the colonic epithelial barrier. The present ﬁ ndings suggest that AM 
could serve as a novel agent for treating refractory ulcerative colitis. 
 Keywords  Endogenous peptide •  Inﬂ ammatory bowel disease •  Autoimmune 
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 Abbreviations 
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 AZA  Azathioprine 
 CD  Crohn’s disease 
 CGRP  Calcitonin gene related peptide 
 CRLR  Calcitonin receptor-like receptor 
 DSS  Dextran sulfate sodium 
 HIF  Hypoxia-induced factor 
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 IELs  Intraepithelial T lymphocytes 
 IFN  Interferon 
 IL  Interleukin 
 iNOS  Inducible nitric oxide synthase 
 IR  Immunoreactive 
 LPS  Lipopolysaccharide 
 PAMP  Proadrenomedullin N-terminal 20 peptide 
 PSL  Prednisolone 
 RAMP  Receptor activity-modifying protein 
 STAT  Signal transducer and activator of transcription 
 TCR  T-cell receptor 
 TGF  Transforming growth factor 
 TNF  Tumor necrosis factor 
 UC  Ulcerative colitis 
 UCDAI  Ulcerative Colitis Disease Activity Index 
 VSMCs  Vascular smooth muscle cells 
 Introduction 
 Inﬂ ammatory bowel disease (IBD) is a refractory ailment, probably involving an 
autoimmune response to one or more as yet unknown triggers in the intestinal tract. 
The etiology of IBD is unknown, but it is thought to involve genetic, immunological, 
and environmental factors. The two major types of IBD are ulcerative colitis (UC) 
and Crohn’s disease (CD). An estimated 1.4 million persons are afﬂ icted with these 
diseases in the USA [ 1 ,  2 ] and the estimated number of patients with IBD in Japan 
has recently increased to over 100,000. Therefore, the number of patients with 
severe and refractory UC has also increased, and consequently, new and effective 
drugs for refractory UC are highly desirable. 
 Adrenomedullin (AM) was originally isolated from a human pheochromocytoma 
as a potent vasodilatory peptide that could elevate levels of platelet cAMP [ 3 ]. 
In addition to hypotension and other properties, AM regulates cellular growth and 
differentiation, stimulates angiogenesis, and modulates hormone secretion. AM also 
appears to inhibit inﬂ ammation and support tissue homeostasis by suppressing the 
synthesis of pro-inﬂ ammatory cytokines and promoting wound healing [ 4 ]. In fact, 
AM ameliorates several types of colitis induced in animal models, and because it is 
an endogenous biologically active peptide, it should be a safe and effective drug for 
the treatment of IBD. 
 This chapter presents general information about AM, its physiological and 
pathophysiological roles within gastrointestinal organs, and its therapeutic effects in 
animal models with colitis and in patients with refractory UC. 
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 Basic Characteristics of AM 
 AM is a biologically active peptide that was initially isolated from a human 
pheochromocytoma arising from the adrenal medulla [ 3 ]. The human AM gene is 
located at the distal end of the short arm of chromosome 11 (p15.1–3) [ 5 ]. The AM 
protein expressed in humans is composed of 52 amino acids (Fig.  1 ) and it belongs 
to the calcitonin peptide superfamily, which also includes calcitonin gene-related 
peptide (CGRP), amylin, and adrenomedullin-2/intermedin [ 6 ]. Functional AM or 
CGRP receptors comprise calcitonin receptor-like receptor (CRLR) and a receptor 
activity- modifying protein (RAMP) [ 7 ]. Three types of RAMP are expressed in 
mammalian tissue, and CRLR can function as either a CGRP receptor or an AM 
receptor, depending on the co-expressed RAMP subtype (Fig.  1 ).
 The precursor of human AM (human preproAM) comprises 185 amino acids and 
includes the AM sequence [ 8 ]. In addition to AM, proadrenomedullin (proAM) con-
tains a novel 20-residue peptide called proadrenomedullin N-terminal 20 peptide 
(PAMP), which is also processed from the AM precursor (Fig.  1 ), but PAMP is not 
discussed here. 
 AM is essentially ubiquitous in human tissues. Immunoreactive AM has been 
identiﬁ ed in cardiovascular, renal, respiratory, gastrointestinal, reproductive, 
preproAM









 Fig. 1  Processing and biosynthesis of AM and PAMP from preproAM and relationships between 
AM and its receptor. When processed from preproAM, AM-Gly, an intermediate form (iAM), is 
produced and converted by an amidation enzyme to mature AM (mAM) with an amide structure at 
the C-terminal [ 8 ]. The mature form of PAMP is thought to be produced via a similar process. 
CRLR serves as a CGRP receptor when co-expressed with RAMP1, and as an AM type 1 or 2 
(AM1 or AM2) receptor when co-expressed with either RAMP2 or RAMP3, respectively [ 7 ] 
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 neurological, endocrine, and immune tissues [ 9 ]. AM is produced in stromal as well 
as parenchymal cells, and numerous factors can inﬂ uence its synthesis. For  example, 
cardiovascular hormones such as angiotensin II and endothelin increase AM 
 production in vascular smooth muscle cells (VSMCs). The production of AM is also 
regulated by physical factors such as shear stress, ventricular wall stress, and 
hypoxia, as well as by inﬂ ammatory cytokines such as tumor necrosis factor 
(TNF)-α and interleukin (IL)-1 [ 11 ]. Lipopolysaccharide (LPS) also stimulates the 
synthesis and secretion of AM in endothelial cells, VSMCs, and various other cell 
types [ 10 ]. 
 AM has generally been characterized as a cardiovascular hormone. Consistent 
with such a classiﬁ cation, AM is an essential cardiovascular peptide involved in 
regulating the circulation and controlling body ﬂ uids. In addition, AM reportedly 
exerts angiogenic, lymphangiogenic, antioxidant, tissue protective and reparative, 
and anti-inﬂ ammatory effects. These multiple biological activities of AM have been 
described in two recent reviews [ 4 ,  11 ]. 
 Pathophysiological Roles of AM in Infl ammation 
 Plasma AM concentrations are elevated in patients with hypertension, congestive 
heart failure, myocardial infarction, or renal diseases, and during the acute phase of 
stroke [ 12 – 14 ]. Two molecular forms of AM circulate in the blood of humans and 
rats; one is a mature form of AM with an amidated C-terminal (AM–NH2), and the 
other is an intermediate form with a non-amidated C-terminal glycine (AM–Gly). 
Plasma and tissue AM concentrations have been measured in several studies, but 
most of them detected immunoreactive AM as total AM comprising AM–NH2 and 
AM–Gly [ 12 ,  13 ,  15 ]. Figure  2 shows a comparison of plasma mature and total AM 
concentrations in several diseases. Both mature and total AM levels in plasma are 







































 Fig. 2  Comparison of plasma concentrations of mature ( a ) and total ( b ) AM in healthy volunteers 
and patients with hypertension, renal failure, and inﬂ ammatory disorders (Modiﬁ ed and redrawn 
from Ohta et al. [ 12 ,  15 ]) 
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 Given its biological activity as a circulation control factor with potent hypotensive 
and natriuretic activity, elevated AM in cardiovascular disease might inhibit disease 
progression. Plasma AM concentrations are also increased in patients with septic 
shock [ 16 ,  17 ], and we also found high levels of plasma AM in patients with UC 
(Fig.  2 ). Pro-inﬂ ammatory cytokines such as TNF-α and IL-1, and LPS can induce 
AM synthesis. Conversely, AM causes the downregulation of inﬂ ammatory 
 cytokines in Swiss 3 T3 ﬁ broblasts [ 18 ] and rat alveolar macrophages [ 19 ]. In addi-
tion, AM possesses immunomodulatory activities that downregulate inﬂ ammatory 
processes in various models, including those of arthritis [ 20 ] and pancreatitis [ 21 ]. 
These findings suggest that beyond having vasorelaxant activity, AM might 
negatively regulate the inﬂ ammatory response. Consistent with this notion, AM 
secretion and plasma levels are both increased in models of endotoxic shock [ 22 ]. 
Furthermore, heterozygous AM knockout mice are signiﬁ cantly more sensitive to 
endotoxic shock than wild-type mice [ 23 ], whereas transgenic mice overexpressing 
AM are resistant to endotoxic shock [ 24 ]. Taken together, these ﬁ ndings suggest 
that AM is an anti-inﬂ ammatory peptide that exerts protective effects in the context 
of endotoxic shock and inﬂ ammatory disorders. 
 AM is also widely distributed in the gastrointestinal tract, and is expressed at 
high levels in the stomach and colon. Immunohistochemical analysis has revealed 
AM-immunoreactive (IR) cells in the pyloric glands, where they also stain  positively 
for chromogranin A and gastrin [ 25 ]. AM-IR cells are also found in the mucosal and 
glandular epithelia of the digestive tract, as well as in the endocrine and neuroendo-
crine systems [ 9 ]. Tissues surrounding gastric ulcers stain intensely for AM [ 26 ], 
and AM expression in these regions tends to increase during the healing and  scarring 
stages of gastric ulcers, suggesting that AM is involved in gastric mucosal healing. 
Indeed, AM has signiﬁ cant ulcer-healing activities in animal models of gastric 
ulcers [ 27 ,  28 ]. The mechanism through which AM stimulates ulcer healing is 
presumed to involve the preservation of gastric blood ﬂ ow, the inhibition of gastric 
acid secretion, the stimulation of angiogenesis, and the proliferation of mucosal 
epithelial cells. On the other hand, AM expression is increased in human colon 
cancer cells [ 29 ,  30 ]. Thus, AM may contribute to the pathogenesis of colon cancer 
through its ability to stimulate angiogenesis and cell proliferation. 
 Preclinical Pharmacological Effect of AM in Experimental 
Model of Colitis 
 As summarized above, AM apparently exerts anti-inﬂ ammatory effects by inhibit-
ing the expression of TNF-α and IL-1β, and it protects against experimentally 
induced ulcers of the gastric mucosa. AM immunoreactivity has been detected 
throughout the gastrointestinal tract, with concentrations being comparably high in 
the stomach and colon [ 25 ]. Although little is understood about the physiological 
and pathophysiological functions of AM in the gastrointestinal tract, these ﬁ ndings 
suggest that endogenously expressed AM in the colon could play an important 
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protective role against inﬂ ammatory bowel diseases. To test this hypothesis, we 
assessed the effect of synthetic AM on acetic acid–induced colitis and cytokine 
production [ 31 ]. Colitis was induced using the method of Kojima et al. [ 32 ], after 
which AM or saline was administered anally once a day for 3–10 days. The syn-
thetic AM signiﬁ cantly reduced the size and severity of the ulcerative lesions and 
also reduced edema (Fig.  3a, b ). Microscopically, less severe ulceration, reduced 
edema, and milder inﬁ ltration of the lamina propria by inﬂ ammatory cells were 
found in samples of colonic mucosa from rats treated with AM. Furthermore, IL-6 
levels in the affected tissues were signiﬁ cantly lower in AM-treated rats than in 
control rats. On the other hand, AM did not signiﬁ cantly affect levels of interferon-γ 
(IFN-γ). The ability of AM to reduce areas of ulceration was dose dependent, with 
the beneﬁ cial effect of AM waning somewhat at higher doses (Fig.  3c ).
 We further evaluated the effects of AM and its mechanism of action in dextran 
sulfate sodium (DSS)–induced colitis, a popular experimental model of UC, 
focusing on epithelial barrier function [ 33 ,  34 ]. Control mice given DSS developed 
profound and sustained weight loss with symptoms of diarrhea and hematochezia 
(a major symptom of colitis) whereas body weight was maintained and clinical 
symptoms were suppressed in mice treated with AM. Histological analysis of tissue 
 samples collected from control mice on day 10 after DSS administration revealed 





























 Fig. 3  Macroscopic and histological appearance of colonic ulcers induced by subserosal injection 
of acetic acid. Rats were treated with saline ( a ) or AM ( b ) for 5 days. Rats given AM had milder 
ulceration and less edema. Effects of AM (0.25–50.0 μg/day) on acetic acid–induced colonic 
ulcers at 5 days after induction ( c ) ( n = 5 per group). AM dose-dependently reduced the ulcer area, 
but this effect was diminished at higher doses (Modiﬁ ed and redrawn from Ashizuka et al. [ 31 ]) 
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endothelial erosions, and destroyed epithelial integrity. In contrast, the mice treated 
with AM exhibited far less severe histological manifestations, although the colon 
wall had become mildly thickened. Intestinal intraepithelial T lymphocytes (IELs) 
are essential for maintaining epithelial function and preventing inﬂ ammatory 
responses, and we found that IELs isolated from the large intestine of AM-treated 
mice consistently produced less IFN-γ, TNF-α, and IL-6 than those from control 
mice, and that production of transforming growth factor-β (TGF-β) was induced. 
The induction of DSS colitis leads to changes in IEL proﬁ les, with a relative 
decrease in the numbers of T cell receptor (TCR)γδ + cells that express TGF-β and 
might suppress inﬂ ammation by acting as regulatory T cells. Treating mice with 
AM prevents the TCRγδ IEL population from becoming reduced, which would in 
turn inhibit the production of inﬂ ammatory cytokines and increase the production of 
TGF-β, thus suppressing signal transducer and activator of transcription (STAT)-3 
and STAT-1 activation in epithelial cells. The mRNA expression of junctional 
 molecules that contribute to the structure and function of tight junctions is obviously 
reduced in DSS colitis. However, such a reduction is much smaller in AM-treated 
mice, which might contribute to the suppression of the disease trajectory. 
 AM also exerts potent activity against various bacteria [ 35 ,  36 ]—for example, 
 Escherichia coli —and the fact that the AM distribution within the mucosa is very 
similar to that of the defensin family of proteins [ 36 ] suggests that AM may also 
help defend against infection. In addition, the gastrointestinal tracts of AM-treated 
mice contain signiﬁ cantly fewer bacterial anaerobes than those of control mice [ 33 ]. 
The numbers of facultative anaerobes reportedly correlate with IBD activity in 
humans [ 37 ] and thus AM may protect against disruption of the mucosal epithelium 
through the suppression and translocation of anaerobes in the intestinal mucosa. 
 Reports from other laboratories also suggest that AM exerts beneﬁ cial effects 
against experimental models of colitis. For example, AM suppresses the 
 inﬂ ammatory response and mediates the partial regeneration of mucosal immune 
tolerance in a model of TNBS-induced colitis, which reﬂ ects severe IBD [ 38 ]. In 
addition, AM is an efﬁ cient counter-regulatory agent that protects and improves 
the microcirculation that becomes adversely affected by cyclooxygenase (COX)-2 
and inducible nitric oxide synthase (iNOS)/NO abnormalities during inﬂ amma-
tion [ 39 ,  40 ]. Hayashi et al. recently reported that AM ameliorates DSS-induced 
colitis, possibly via suppression of the systemic and local production of cytokines, 
such as TNF-α and IL-6, which accelerate ulcer healing and colonic mucosal 
regeneration [ 41 ]. AM also appears to reduce inﬂ ammatory indices and histological 
inﬂ ammation in DSS-induced murine colitis, and these beneﬁ cial effects are 
 associated with mucosal protection through the ﬁ ne tuning of hypoxia-induced 
factor (HIF) activity [ 42 ]. 
 Given its effectiveness in these experimental models of colitis, we suggest that 
AM has potential as a novel agent for the treatment of IBD, and that it works by 
exerting anti-inﬂ ammatory and antibacterial effects and by stimulating mucosal 
regeneration and helping to maintain the colonic epithelial barrier. 
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 Exploratory Clinical Study of AM as a Therapeutic Agent 
for Refractory Ulcerative Colitis 
 AM confers beneﬁ ts upon patients with cardiovascular diseases such as myocardial 
infarction, congestive heart failure, hypertension, pulmonary hypertension, and 
limb ischemia. The ﬁ rst clinical pilot study of intravenous AM in patients with acute 
myocardial infarction [ 43 ] found that an infusion of 12.5–25 ng/kg/min of AM for 
12 h did not signiﬁ cantly affect the hemodynamic parameters of the patients, but 
signiﬁ cantly improved the wall motion index in infarct areas at 3 months post- 
infarction, compared with baseline. Intravenously infused AM thus appears to exert 
potentially protective cardiovascular effects without severe adverse effects, which 
allows it to serve as a possible adjunct to percutaneous coronary intervention. 
 We found that AM infusions cause similar and steady decreases in blood  pressure 
(Fig.  4a ) and several markers of arteriosclerosis (such as pulse wave velocity) in 
patients with essential hypertension and primary aldosteronism (PA) [ 44 ,  45 ]. The 
infused AM suppressed aldosterone release to values within the normal range in 
the PA group, but had limited effect in the control group and did not alter adreno-
corticotropic hormone–cortisol system in both groups (Fig.  4b ). An infusion of AM 
(15 ng/kg/min) induced an increase of circulating C-reactive protein (CRP) in all 
participants, which suggests that AM can inhibit or stimulate inﬂ ammation, depending 
upon the milieu. Consistent with this notion, AM downregulates TNF-α, an important 
mediator of cytokine production, in macrophages and Swiss 3 T3 cells [ 18 ,  19 ], but 
stimulates IL-6 production in NR8383 and Swiss 3 T3 cells [ 46 ,  47 ]. Furthermore, 
bell-shaped dose-response curves (Fig.  3c ) suggest that the beneﬁ cial effect of AM 
on ulcerative area is dose dependent, and that this effect tends to wane at higher 
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 Fig. 4  Changes in blood pressure ( a ) and plasma aldosterone levels ( b ) during infusion of AM or 
vehicle in patients with essential hypertension and primary aldosteronism (Modiﬁ ed and redrawn 
from Ashizuka et al. [ 48 ]) 
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IBD. Therefore, we clinically treated UC by administering AM at a dose of 9 ng/kg/
min, which does not evoke severe hypotension or stimulate CRP production. Below, 
we describe the ﬁ rst patient with UC whom we treated using AM. The excellent 
results indicated that AM can effectively treat refractory UC [ 48 ,  34 ].
 A 68-year-old woman who was undergoing treatment for diabetes presented with 
a 3-year history of refractory UC. During previous ﬂ are-ups, clinical remission was 
achieved using a high-dose steroid infusion and leukocytapheresis, but insufﬁ cient 
mucosal repair required a regimen of continuous prednisolone (PSL) with azathio-
prine (AZA). However, the patient’s condition worsened, with symptoms of severe 
abdominal pain and bloody stools. Colonoscopy revealed deep ulcerations and ero-
sions throughout the large intestine (Fig.  5a ). Higher doses of PSL in combination 
with leukocytapheresis failed to induce remission (Ulcerative Colitis Disease 
Activity Index (UCDAI) score: 7). After ischemic heart disease, cerebrovascular 
disease, and malignancy were ruled out, AM (9 ng/kg/min) was intravenously 
administered for 12 days (8 h/day), which alleviated the abdominal pain and bloody 
stool after a few days. No adverse effects occurred except for a slight decline in 
blood pressure. Colonoscopy 2 weeks later revealed signiﬁ cant mucosal regenera-
tion (Fig.  5b ), which gastroenterologists had never encountered before, and the 
patient’s UCDAI score had declined to 2. Colonoscopy 3 months later revealed that 
 Fig. 5  Colonoscopy ﬁ ndings: ( a ) before; ( b ) 2 weeks after; ( c ) 3 months after; and ( d ) 12 months 
after treatment with AM (Modiﬁ ed from Ashizuka et al. [ 48 ]) 
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all of the colonic lesions had healed with scarring and the patient’s UCDAI score 
had reached 0, which prompted withdrawal of the PSL (Fig.  5a ). Thus, AM appears 
to be effective against refractory UC in animal models of colitis and for patients 
with refractory UC.
 Table  1 summarizes the comparison of AM therapy and existing methods 
 currently used to treat IBD that all act through the induction and maintenance of 
remission [ 2 ,  34 ]. These include aminosalicylates (5-ASA), steroids (prednisolone), 
immune modiﬁ ers (azathioprine, 6-MP and methotrexate), and biologics (inﬂ ix-
 Table 1  Comparison of AM therapy and methods currently used to treat IBD 
 Agent  Mechanism  Merit  Demerit 
 Anti-inﬂ ammatory 
agent 
 Inhibition of LTB4 
production 
 Safety  Insufﬁ cient for severe 
UC 
 SASP/5-ASA  Removal of reactive 
oxygen 





 Cumulative toxicity 
(metabolic 
abnormality) 
 Predonisolone  Inhibition of cell 
proliferation and 
differentiation 
 Susceptibility to 
infection 
 Inhibition of cell 
inﬁ ltration 
 Immunosuppressor  Inhibition of DNA 
synthesis 
 Maintenance of 
remission 
 Myelosuppression 
 Azathioprine/6MP  Immunosuppressor  Susceptibility to 
infection 
 Malignant lymphoma? 
 Immunosuppressor  Inhibition of IL-2  Potent anti-
inﬂ ammatory 
effect 
 Monitoring the 
concentration in blood 
 Cyclosporine, 
Tacrolims 
 Susceptibility to 
infection 
 Finger tremor, Renal 
damage 
 Anti-cytokine agent  Anti-TNF-α  Potent anti-
inﬂ ammatory 
effect 
 Tachyphylaxis, Allergy 
 Susceptibility to 
infection (tuberculosis) 
 Inﬂ iximab, 
Adalimumab 
 Malignant lymphoma? 
 Blood component 
removal 
 Removal of activated 
leukocyte 
 Safety  Delayed effect 
(~2 weeks) 
 LCAP/GMA  Troublesome 
 Endogenous peptide  Mucosal healing  Safety  Hypotensive effect 
 Adrenomedullin  Inhibition of inﬂ ammatory 
cytokines 
 New mechanism 
 Angiogenesis, 
Amelioration of ischemia 
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imab). However, the results obtained with these medications are not completely 
satisfactory in about one quarter of UC patients, as their effects are either insufﬁ -
cient or lead to complications. Surgical treatment (colectomy) may be considered 
for such patients.
 In addition to conventional steroid therapy, immune modiﬁ ers or biologics are 
commonly used to treat steroid-resistant or steroid-dependent refractory 
UC. Although these therapies can be effective, potentially serious infections such as 
fungal diseases and tuberculosis are a concern, especially in patients with diabetes 
mellitus. In addition, immune modiﬁ ers can cause malignant lymphoma in young 
patients. Therefore, new and effective drugs that lack these adverse side effects 
are highly desirable. We found that a continuous intravenous infusion of AM 
ameliorated the symptoms of intractable UC without adverse side effects. Moreover, 
endoscopic evaluation after AM therapy showed remarkable mucosal regeneration 
and healing with neovascularization at previously ulcerative or erosive lesions. 
These results suggest that AM is a potentially useful therapeutic agent with a novel 
mechanism of action that involves anti-inﬂ ammatory effects with mucosal and 
 vascular regeneration. 
 Conclusion 
 Here, we have provided general information about AM, its physiological and patho-
physiological roles in the gastrointestinal tract, and translational research demonstrating 
the safety and value of AM for treating refractory UC. AM is a multifunctional cardio-
vascular hormone that exerts curative effects on cardiocirculatory dynamics. Thus, AM 
has been investigated mainly in the context of cardiovascular disease. However, AM can 
also protect organs and regenerate tissues, and it exerts anti- inﬂ ammatory and angio-
genic effects while stimulating epithelial and mucosal cell proliferation. This suggests 
that AM could help to treat various diseases in addition to cardiovascular disease. With 
respect to its use in the treatment of refractory UC, AM has no antigenicity because it is 
an endogenous peptide. Moreover, its mode of action differs from those of existing 
immunomodulators such as steroids, immune modiﬁ ers, and biologics. Additional study 
is required to conﬁ rm whether or not AM could treat refractory UC. 
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